

# INSTITUTIONAL BIOSAFETY COMMITTEE

## Meeting Minutes

February 24, 2022  
1<sup>st</sup> Floor Conference Room & MS Teams Teleconference  
11:30 am - 1:00 pm



### Attendance:

IBC Member/Staff	Affiliation/Role	Present	Absent
B.J.	IBC Chair	X	
J.C.O.	Biological Safety Officer/Vice Chair	X	
A.H.	Veterinarian	X	
B.S.	Microbiologist	X	
K.C.	Molecular Biologist, Virologist	X	
J.H.B.	Virologist	X	
G.H.	Bacteriologist / Technician Representative	X	
A.E.	Bacteriologist / Technician Representative		X
B.H.	Nonaffiliated Member	X	
B.C.	Nonaffiliated Member	X	
L.H.	Nonaffiliated Member	X	
B.T.	Alternate, Biological Safety Officer	X	
J.L.B.	IBC Staff	X	

### Guests in Attendance: A.S.

#### 1. Call to Order

1.1 B.J. called the meeting to order at 11:35 am.

#### 2. Roll Call

2.1 A quorum was verified.

#### 3. Approval of Meeting Minutes

3.1. The December 23, 2021, meeting minutes were reviewed and unanimously approved via email on January 11, 2022.

#### 4. Ongoing Business

4.1 N/A

#### 5. New Business

5.1. The committee reviewed a newly submitted registration, IBC-22-0074. The PI gave a summary of the project and answered the committee's questions. B.H. made a motion to approve the registration. G.H. seconded the motion, and the committee unanimously approved the registration.

5.2. There were no additional registrations received since the last meeting.

- 5.3. A deviation report was received from a PI on January 3, 2022 regarding IBC-20-0058. The deviation occurred when it was noticed cell lines were used that were not captured in the original registration. After immediate reporting to the IBC, the IBC Chair, Vice Chair, and RCM reviewed the report and determined it did not constitute a significant event and did not require further reporting to the institutional official or NIH/OBA, just notification to the IBC. Afterwards, the PI submitted an amendment to broaden the scope of the mammalian cell lines. The committee had no questions.
- 5.4. The IBC Chair updated the committee on the following amendments that were approved since the last meeting:
  - IBC-20-0058 was reviewed via DMR and approved on January 19, 2022.
  - IBC-18-0042 was administratively reviewed and approved on January 24, 2022.
  - IBC-21-0068 was reviewed via DMR and approved on February 1, 2022.
  - Two amendments for IBC-21-0073 were reviewed; one via DMR and approved on February 2, 2022, and the other administratively and approved on February 14, 2022.
- 5.5. There were two Etiologic Agent Registrations (#319 and #320) that were received and distributed to the committee for their information. The committee had no questions or concerns.

## 6. Training – N/A

## 7. Action Items

- 7.1. None

## 8. Housekeeping Items

- 8.1. The next meeting is scheduled for Thursday, March 24, 2022, from 11:30 am - 1:00 pm in the NBACC Building and Teams Teleconference.

## 9. Adjourn

- 9.1 A motion was made by J.C.O. and seconded by K.C. to adjourn the meeting at 12:10 pm.

This work was funded under Agreement No. HSHQDC-15-C-00064 awarded to Battelle National Biodefense Institute by the Department of Homeland Security (DHS) Science and Technology (S&T) Directorate for the management and operation of the National Biodefense Analysis and Countermeasures Center (NBACC), a Federally Funded Research and Development Center. The views and conclusions contained in this document are those of the authors and should not be interpreted as necessarily representing the official policies, either expressed or implied, of DHS or the U.S. Government. The DHS does not endorse any products or commercial services mentioned in this presentation. In no event shall the DHS, BNBI or NBACC have any responsibility or liability for any use, misuse, inability to use, or reliance upon the information contained herein. **In addition, no warranty of fitness for a particular purpose, merchantability, accuracy or adequacy is provided regarding the contents of this document.**

All research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals and approved by both the NBACC Institutional Animal Care and Use Committee and, when applicable, the DHS Compliance and Assurance Program Office. The facility where this research was conducted is fully accredited by AAALAC International and maintains a Public Health Service (PHS) Humane Care and Use of Laboratory Animals (Policy) assurance.